LifeMD (NASDAQ:LFMD) Announces Earnings Results

LifeMD (NASDAQ:LFMD) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01), FiscalAI reports. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The company had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million.

Here are the key takeaways from LifeMD’s conference call:

• Q2 profitability missed expectations: Revenue was $47.3 million, but adjusted EBITDA was a $3.5 million loss due to elevated customer acquisition costs and the $39 introductory weight-management offer.
• LifeMD reduced its full-year 2026 outlook to revenue of $205.5 million–$212.5 million and adjusted EBITDA ranging from a $6 million loss to breakeven, while the XYOSTED launch is expected to require $2 million–$3 million of investment this year.
• Underlying business economics improved, with recurring-bill revenue at approximately 84% of total revenue, gross margin expanding to 89%, and sequential reductions of $1.8 million in advertising and $1.5 million in G&A expenses.
• The $39 weight-management offer shifted new patients toward longer-duration plans, with multi-month selections rising from roughly 25% to 85%; management said recent acquisition costs were about 50% below their June peak.
• Management expects adjusted EBITDA profitability in Q3 and Q4 revenue of $60 million–$64 million with adjusted EBITDA of $3 million–$6 million, supported by women’s health growth, pharmacy expansion, insurance initiatives, and new pharmaceutical partnerships.

LifeMD Stock Performance

NASDAQ LFMD traded down $0.28 during mid-day trading on Thursday, reaching $3.40. 4,971,531 shares of the stock were exchanged, compared to its average volume of 1,098,763. The business’s 50 day moving average is $4.43 and its 200-day moving average is $3.98. LifeMD has a 1 year low of $2.56 and a 1 year high of $7.32. The company has a market capitalization of $164.43 million, a P/E ratio of 68.01 and a beta of 2.02.

LifeMD News Summary

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: BTIG Research maintained a Buy rating while lowering its price target from $10 to $9. The revised target still implies substantial upside, signaling that the firm views the recent selloff as excessive. Benzinga
• Positive Sentiment: B. Riley also retained a Buy rating and reduced its target from $10 to $8, suggesting continued confidence in LifeMD’s longer-term recovery potential. The Fly
• Positive Sentiment: LifeMD reported approximately 356,000 active subscribers, up 20% year over year, while weight-management subscribers reached about 108,000. Gross margin expanded to roughly 89%, and the company said 95% of new weight-management patients now use branded GLP-1 therapies. LifeMD Second Quarter Results
• Neutral Sentiment: Management expects positive adjusted EBITDA in the second half of 2026 and launched a telehealth collaboration for XYOSTED®. LifeMD ended the quarter with $25.1 million in cash, no debt and $30 million of undrawn revolving credit capacity.
• Negative Sentiment: Second-quarter revenue of $47.3 million declined from $49.0 million a year earlier and missed the approximately $49.2 million consensus estimate. The company posted a $0.16-per-share loss, slightly worse than expectations, while adjusted EBITDA remained negative at about $3.5 million. Zacks Q2 Earnings Report
• Negative Sentiment: LifeMD cut full-year 2026 revenue guidance to $205.5 million-$212.5 million from $220 million-$230 million and reduced adjusted EBITDA guidance to a range of a $6 million loss to breakeven, versus prior guidance of $12 million-$17 million. Third-quarter revenue guidance of $48 million-$51 million is also below consensus.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Federated Hermes Inc. increased its position in shares of LifeMD by 278.1% in the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after buying an additional 721,018 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of LifeMD by 1,767.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock worth $5,924,000 after buying an additional 411,651 shares during the period. JPMorgan Chase & Co. lifted its position in shares of LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after buying an additional 352,004 shares in the last quarter. Invesco Ltd. lifted its position in shares of LifeMD by 1,904.0% during the 2nd quarter. Invesco Ltd. now owns 327,080 shares of the company’s stock valued at $4,455,000 after buying an additional 310,759 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its stake in LifeMD by 288.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 309,337 shares of the company’s stock valued at $4,213,000 after acquiring an additional 229,781 shares during the period. Institutional investors and hedge funds own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LFMD shares. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a research note on Tuesday. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Lake Street Capital set a $5.00 price objective on LifeMD in a research note on Thursday. Finally, B. Riley Financial decreased their target price on LifeMD from $10.00 to $8.00 and set a “buy” rating for the company in a report on Thursday. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.14.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.